TY - JOUR
T1 - New Insights into Upper Tract Urothelial Carcinoma
T2 - Lessons Learned from the ROBUUST Collaborative Study
AU - Biasatti, Arianna
AU - Bignante, Gabriele
AU - Ditonno, Francesco
AU - Veccia, Alessandro
AU - Bertolo, Riccardo
AU - Antonelli, Alessandro
AU - Lee, Randall
AU - Eun, Daniel D.
AU - Margulis, Vitaly
AU - Abdollah, Firas
AU - Yoshida, Takashi
AU - Derweesh, Ithaar H.
AU - Meagher, Margaret F.
AU - Simone, Giuseppe
AU - Tuderti, Gabriele
AU - Bologna, Eugenio
AU - Mehrazin, Reza
AU - Rais-Bahrami, Soroush
AU - Sundaram, Chandru P.
AU - Yong, Courtney
AU - Minervini, Andrea
AU - Mari, Andrea
AU - Lambertini, Luca
AU - Ferro, Matteo
AU - Singla, Nirmish
AU - Pandolfo, Savio D.
AU - Amparore, Daniele
AU - Checcucci, Enrico
AU - Gonzalgo, Mark L.
AU - Porter, James R.
AU - Ghoreifi, Alireza
AU - Contieri, Roberto
AU - Perdonà, Sisto
AU - Porpiglia, Francesco
AU - Djaladat, Hooman
AU - Ghodoussipour, Saum
AU - Autorino, Riccardo
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/5
Y1 - 2025/5
N2 - Upper tract urothelial carcinoma (UTUC) is a rare malignancy, representing only 5–10% of urothelial carcinoma. The mainstay of treatment for high-risk patients is radical nephroureterectomy. Given the aggressive behavior of this disease, additional treatments could be required perioperatively in terms of chemotherapy (CHT), either in a neoadjuvant or adjuvant setting. On the other hand, low-risk and selected cases can be managed with kidney-sparing surgery (KSS). The ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) is an ongoing international, multicenter registry of patients undergoing surgery for UTUC. After conducting a literature search in February 2025 using the MEDLINE (via PubMed) and Embase databases, we identified 14 studies based on the ROBUUST data analyses. There are several key topics concerning UTUC that remain under debate and were therefore addressed in these studies, focusing on preoperative evaluation and planning, surgical techniques and intraoperative procedures, additional perioperative treatments, and outcomes. The ROBUUST registry has served as a valuable source for a growing body of investigations focusing on various aspects of UTUC treatment planning, decision-making, and outcomes, providing innovative tools and enabling large-scale, novel analyses.
AB - Upper tract urothelial carcinoma (UTUC) is a rare malignancy, representing only 5–10% of urothelial carcinoma. The mainstay of treatment for high-risk patients is radical nephroureterectomy. Given the aggressive behavior of this disease, additional treatments could be required perioperatively in terms of chemotherapy (CHT), either in a neoadjuvant or adjuvant setting. On the other hand, low-risk and selected cases can be managed with kidney-sparing surgery (KSS). The ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) is an ongoing international, multicenter registry of patients undergoing surgery for UTUC. After conducting a literature search in February 2025 using the MEDLINE (via PubMed) and Embase databases, we identified 14 studies based on the ROBUUST data analyses. There are several key topics concerning UTUC that remain under debate and were therefore addressed in these studies, focusing on preoperative evaluation and planning, surgical techniques and intraoperative procedures, additional perioperative treatments, and outcomes. The ROBUUST registry has served as a valuable source for a growing body of investigations focusing on various aspects of UTUC treatment planning, decision-making, and outcomes, providing innovative tools and enabling large-scale, novel analyses.
KW - ROBUUST 2.0
KW - ROBUUST registry
KW - UTUC
KW - Upper Tract Urothelial Carcinoma
KW - Urologic Oncology
UR - https://www.scopus.com/pages/publications/105006558732
U2 - 10.3390/cancers17101668
DO - 10.3390/cancers17101668
M3 - Review article
AN - SCOPUS:105006558732
SN - 2072-6694
VL - 17
JO - Cancers
JF - Cancers
IS - 10
M1 - 1668
ER -